One week’s treatment with the long-acting glucagon-like peptide-1 derivative Liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogeneous glucose release in patients with type 2 Diabetes. - Degn,K.; Juhl,C.; Sturis,J. (Diabetes, 2004)